Ernst Kubista

TL;DR: Everolimus significantly increased letrozole efficacy in neoadjuvant therapy of patients with ER-positive breast cancer and the safety profile was consistent with historical results of everolimus monotherapy.

TL;DR: The results indicate that patients with advanced-stage breast cancers might profit from future therapies targeting HIF-1alpha, an independent prognostic factor for an unfavorable prognosis in patients with lymph node-positive breast cancer.

TL;DR: A randomised, open-label, phase III, 4-arm trial comparing tamoxifen and goserelin versus anastrozole and zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuant treatment with or without zoledronics acid.

TL;DR: Overall, the data suggest that the goserelin-tamoxifen combination is significantly more effective than CMF in the adjuvant treatment of premenopausal patients with stage I and II breast cancer.

TL;DR: These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole compared with no further treatment and investigate the possibility of tailoring this period to suit different disease types.